RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia

Leukemias are routinely sub-typed for risk/outcome prediction and therapy choice using acquired mutations and chromosomal rearrangements. Down syndrome acute lymphoblastic leukemia (DS‐ALL) is characterized by high frequency of CRLF2‐rearrangements, JAK2‐mutations, or RAS‐pathway mutations. Intrigui...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncogene
Hauptverfasser: Koschut, David, Ray, Debleena, Li, Zhenhua, Giarin, Emanuela, Groet, Jürgen, Alić, Ivan, Kham, Shirley Kow-Yin, Chng, Wee Joo, Ariffin, Hany, Weinstock, David M., Yeoh, Allen Eng-Juh, Basso, Giuseppe, Nižetić, Dean
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group UK 2020
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7843419/
https://ncbi.nlm.nih.gov/pubmed/33247204
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41388-020-01567-7
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge